Literature DB >> 10071788

Partial agonism: mechanisms based on ligand-receptor interactions and on stimulus-response coupling.

V Pliska1.   

Abstract

Substances eliciting, at very high concentrations, a lower maximal response of a particular biological system than a defined standard, are defined as partial agonists. The convention rests on the definition of a standard substance that achieves a 'full' maximal response; partial agonism being, therefore, relative. Various mechanisms lie behind this phenomenon: 1. Receptor-related mechanisms: the agonist-receptor complex exists in several conformational states from which only one, or only a few, activate the cell signaling pathway. This may occur when the receptor itself, or the agonist, exists in multiple states (e.g., in the form of enantiomers or stereoisomers), or when the agonist-receptor complex changes its conformation (receptor switch: two-state model of receptor activation). Furthermore, a steric hindrance by a 'wrong-way binding' of a part of the agonist's molecules may prevent the full 'correct' occupancy of receptors. 2. Mechanisms based on the efficacy of the stimulus-response coupling. The efficacy is then proportional to the sum of probabilities that receptors in individual states activate the cell-signaling pathway. Doses (concentrations) eliciting the half maximal response (EC50), or similar response sensitivity parameters, are not included in the definition of partial agonism. However, tight correlations exist between maximal response and EC50 in many, but not all, generic groups of agonistically acting substances. These relationships are frequently linear; intercepts and slopes of these 'E, KE plots' are characteristic for individual, putative mechanisms. Dose-response curves of partial agonists are akin to those obtained for a response to a full agonist after a stepwise partial inactivation of receptors by an irreversible inhibitor. Also, the E, KE plots obtained in these instances are similar to those of partial agonists. The receptor reserve, rather vaguely defined in early reports, is therefore closely linked to the phenomenon of partial agonism.

Mesh:

Substances:

Year:  1999        PMID: 10071788     DOI: 10.3109/10799899909036675

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  4 in total

1.  Mycobacterium tuberculosis chaperonin 60.1 is a more potent cytokine stimulator than chaperonin 60.2 (Hsp 65) and contains a CD14-binding domain.

Authors:  J C Lewthwaite; A R Coates; P Tormay; M Singh; P Mascagni; S Poole; M Roberts; L Sharp; B Henderson
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

2.  Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide.

Authors:  Paolo Ambrosino; Maria Virginia Soldovieri; Claudio Russo; Maurizio Taglialatela
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

3.  Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist.

Authors:  Caleb R Glassman; Leon Su; Sonia S Majri-Morrison; Hauke Winkelmann; Fei Mo; Peng Li; Magdiel Pérez-Cruz; Peggy P Ho; Ievgen Koliesnik; Nadine Nagy; Tereza Hnizdilova; Lora K Picton; Marek Kovar; Paul Bollyky; Lawrence Steinman; Everett Meyer; Jacob Piehler; Warren J Leonard; K Christopher Garcia
Journal:  Elife       Date:  2021-05-18       Impact factor: 8.140

4.  Concentration-dependent effects of native and polymerised alpha1-antitrypsin on primary human monocytes, in vitro.

Authors:  Ruta Aldonyte; Lennart Jansson; Sabina Janciauskiene
Journal:  BMC Cell Biol       Date:  2004-03-29       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.